Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Oral Abstract: IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

Elizabeth L Budde,Laurie H Sehn,Matthew Matasar,Stephen J Schuster,Sarit Assouline,Pratyush Giri,John Kuruvilla,Miguel Canales,Sascha Dietrich,Keith Fay,Matthew Ku,Loretta Nastoupil,Michael C Wei,Shen Yin,Michelle Y Doral,Chi-Chung Li,Huang Huang,Raluca Negricea,Elicia Penuel,Carol O'Hear

Clinical Lymphoma Myeloma and Leukemia（2022）

Cited 0|Views17
No score
Abstract
Mosunetuzumab induces high CR rates and durable remissions in patients with R/R FL and ≥2 prior therapies. Mosunetuzumab has favorable safety, allowing administration without mandatory hospitalization.
More
Translated text
Key words
IBCL,mosunetuzumab,bispecific antibody,relapsed/refractory,follicular lymphoma,Phase I/II
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined